Chip Somodevilla/Getty Images

The US Supreme Court will hold a hearing on the biosimilar patent case Amgen v. Sandoz next week to decide whether companies must exchange patent and manufacturing information before FDA approval and whether manufacturers must wait an extra six months after FDA approval before they can market new biosimilars. A final decision is expected by July.

Full Story:
Regulatory Focus

Related Summaries